BMS-986460 for Healthy Subjects

Recruiting in Palo Alto (17 mi)

+1 other location

Age: 18 - 65

Sex: Male

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Bristol-Myers Squibb

No Placebo Group

Trial Summary

What is the purpose of this trial?The purpose of this study is to assess the safety, tolerability, drug levels, and relative bioavailability of alternate formulations of BMS-986460 in healthy adult male participants.

Eligibility Criteria

This trial is for healthy adult men who can participate in a study to test different forms of a drug called BMS-986460. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and not be taking conflicting medications.

Inclusion Criteria

Participants must have a Body mass index (BMI) between 18.0 and 35.0 kilograms/meter square (kg/m2), inclusive

I agree to use birth control if I'm sexually active with someone who can get pregnant.

I am generally healthy with no significant medical issues.

Exclusion Criteria

Participants with left ventricular ejection fraction (≤ 50%) at screening are excluded

Other protocol-defined Inclusion/Exclusion criteria apply

Participants with history of anaphylactic reactions are excluded

+3 more

Participant Groups

The study is testing the safety and how the body absorbs different versions of BMS-986460. It's a single-dose trial, meaning each participant will receive one dose of the medication to evaluate its effects.

8Treatment groups

Experimental Treatment

Group I: Part 2: Treatment BExperimental Treatment1 Intervention

Group II: Part 2: Treatment AExperimental Treatment1 Intervention

Group III: Part 2: Optional Treatment EExperimental Treatment1 Intervention

Group IV: Part 2: Optional Treatment DExperimental Treatment1 Intervention

Group V: Part 2: Optional Treatment CExperimental Treatment1 Intervention

Group VI: Part 1: Sequence 3Experimental Treatment1 Intervention

Group VII: Part 1: Sequence 2Experimental Treatment1 Intervention

Group VIII: Part 1: Sequence 1Experimental Treatment1 Intervention